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ARTICLE
Loss of 5-methylcytosine alters the biogenesis
of vault-derived small RNAs to coordinate
epidermal differentiation
Abdulrahim A. Sajini1,2,3, Nila Roy Choudhury4, Rebecca E. Wagner1, Susanne Bornelöv 5, Tommaso Selmi1,
Christos Spanos 6, Sabine Dietmann5, Juri Rappsilber6,7, Gracjan Michlewski 4,6,8 & Michaela Frye1,9
The presence and absence of RNA modiﬁcations regulates RNA metabolism by modulating
the binding of writer, reader, and eraser proteins. For 5-methylcytosine (m5C) however, it is
largely unknown how it recruits or repels RNA-binding proteins. Here, we decipher the
consequences of m5C deposition into the abundant non-coding vault RNA VTRNA1.1.
Methylation of cytosine 69 in VTRNA1.1 occurs frequently in human cells, is exclusively
mediated by NSUN2, and determines the processing of VTRNA1.1 into small-vault RNAs
(svRNAs). We identify the serine/arginine rich splicing factor 2 (SRSF2) as a novel
VTRNA1.1-binding protein that counteracts VTRNA1.1 processing by binding the non-
methylated form with higher afﬁnity. Both NSUN2 and SRSF2 orchestrate the production of
distinct svRNAs. Finally, we discover a functional role of svRNAs in regulating the epidermal
differentiation programme. Thus, our data reveal a direct role for m5C in the processing of
VTRNA1.1 that involves SRSF2 and is crucial for efﬁcient cellular differentiation.
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The post-transcriptional deposition of chemical modiﬁca-tions into RNA emerged as a crucial regulator of geneexpression programs1. 5-methylcytosine (m5C) occurs in
various RNA molecules and is mediated by at least eight, highly
conserved enzymes (NSUN1-7, and DNMT2) in mammals2. One
of the best-characterised m5C methyltransferase is NSUN2, which
targets the majority of cytoplasmic transfer RNAs (tRNAs) and a
smaller number of coding and other non-coding RNAs including
VTRNAs3–7.
In tRNAs, NSUN2-mediated formation of m5C protects from
endonucleolytic cleavage7,8. Loss of tRNA methylation enhances
the afﬁnity to the endonuclease angiogenin, which then cleaves
the tRNAs causing a global reduction in protein synthesis7,8. The
cellular consequences of NSUN2-deletion are reduced cellular
migration and delayed activation of stem cell differentiation8–10.
NSUN2-mediated RNA methylation is required for normal
development7, and loss-of-function mutations in human NSUN2
gene is associated with neuro-developmental disorders11–14.
The functional role of m5C in VTRNAs is less clear. VTRNAs
are integral components of large ribonucleoprotein vault particles
found in the cytoplasm of most eukaryotic cells15,16. However,
only about 5% of cytoplasmic VTRNA is directly associated to
vault particles and similarly small amounts of VTRNAs are
reported to reside in the nucleus17,18. In humans, four VTRNAs
are expressed VTRNA1.1, VTRNA1.2, VTRNA1.3, and
VTRNA2.116, two of which (VTRNA1.1 and VTRNA1.3) are
methylated by NSUN23. VTRNAs have been implicated in the
cellular immune response, cell survival and oncogenic multi-drug
resistance, indicating a functional role in several fundamental
biological processes17,19–23.
VTRNAs are also processed into smaller regulatory RNAs
(svRNA) by a pathway different from microRNA (miRNA) bio-
genesis21. VTRNA-derived svRNAs are highly abundant in exo-
somes, and at least some of them regulate gene expression
similarly to miRNAs3,21,24,25. We previously revealed that the
processing of full-length VTRNA1.1 into svRNAs depended on
the methylation of cytosine 69 (C69)3, yet the underlying mole-
cular mechanisms and the functional role of the svRNAs
remained unknown.
Here, we performed mass spectrometry-based quantitative
proteomics to identify all proteins whose binding afﬁnity is
directly determined by the presence or absence of m5C69 in
VTRNA1.1. We identify SRSF2 as a novel VTRNA-binding
protein that is repelled by m5C69. By binding the un-methylated
form with higher afﬁnity, SRSF2 protects VTRNA1.1 from pro-
cessing. We conﬁrm that both NSUN2 and SRSF2 coordinate the
processing of VTRNA1.1 into speciﬁc svRNAs. Functionally, we
show that the presence of one speciﬁc VTRNA-derived small
non-coding RNA (svRNA4) is sufﬁcient to alter the transcrip-
tional program needed to induce epidermal differentiation.
Together, we demonstrate that the deposition of m5C orchestrates
VTRNA1.1 processing and thereby determines its downstream
biological function.
Results
Methylation of VTRNA1.1 requires NSUN2. NSUN2 methy-
lates the vast majority of tRNAs and a small number of coding
and non-coding RNAs1. To determine which of these methylated
sites solely depended on NSUN2, we rescued human dermal
ﬁbroblasts lacking a functional NSUN2 protein (NSUN2−/−) by
re-expressing NSUN2 or an enzymatic dead version of the
enzyme (K190M)11,26. We conﬁrmed cytosine- methylation using
RNA bisulﬁte (BS) sequencing7. As expected, the methylation
levels between NSUN2−/− cells infected with the empty vector
control and the enzymatic dead NSUN2 (K190M) highly
correlated (Fig. 1a). In contrast, methylation of more than
100 sites signiﬁcantly increased when NSUN2 was re-expressed
(Fig. 1b; Supplementary Data 1). We conﬁrmed that the NSUN2
and K190M proteins were equally expressed in the rescued
NSUN2−/− cells (Supplementary Fig. 1a).
In addition to tRNAs, we conﬁrmed NSUN2-speciﬁc methyla-
tion of cytosine (C) 69 in VTRNA1.1 (Fig. 1c)3. Furthermore, we
identiﬁed a small number of novel high-conﬁdence sites in both
coding and non-coding RNAs (Supplementary Fig. 1b-e).
NSUN2-dependent methylation sites in VTRNAs, RPPH1, and
HECTD1 for instance, were consistently methylated in human
cells, including HEK293 and human embryonic stem cells (H9)
(Fig. 1d, e). Notably, the methylation levels of C69 in VTRNA1.1
varied and were usually lower than 50%, even when NSUN2 was
over-expressed (Fig. 1c–e; left hand panels). We concluded that
methylation of VTRNA1.1 at C69 occurred at dynamic levels but
was widely present in human cells.
VTRNA1.1 methylation determines the biogenesis of svRNA4.
The functional relevance of C69 methylation in VTRNA1.1 was
unknown. However, our previous study demonstrated that the
presence and absence of m5C correlated with the differential
processing of VTRNA1.1 into small non-coding RNA fragments
(svRNA1-4) (Supplementary Fig. 1f)3. Of these svRNAs, only the
length of svRNA4 coincided with C69 (Fig. 1f; Supplementary
Fig. 1f). SvRNA4 was more abundant in human dermal ﬁbro-
blasts expressing NSUN2 (Fig. 1g), indicating that the formation
of svRNA4 was enhanced when VTRNA1.1 carried m5C6911. We
asked whether the presence of m5C69 increased the formation of
svRNA4 and quantiﬁed svRNA4 in NSUN2−/− cells re-
expressing the wild-type (wt) or enzymatic dead versions of
NSUN2 (C321A; C271A)8,26. The processing of VTRNA1.1. into
svRNA4 depended on the methylation activity of NSUN2 because
only the wild-type construct of NSUN2 increased svRNA4 pro-
duction (Fig. 1g). All over-expressed constructs were equally up-
regulated in the NSUN2−/− cells (Fig. 1h)8. Thus, the presence of
a methylation group at C69 enhanced the processing of VTRN1.1
into svRNA4.
Proteins binding to un-methylated and methylated VTRNA1.1.
To dissect how VTRNA1.1 processing was regulated, we sought
to identify all RNA-binding proteins showing a higher afﬁnity to
methylated or un-methylated VTRNA1.1. We performed quan-
titative RP-SMS (RNA pull-down SILAC (stable isotope labeling
with amino acids in cell culture) mass spectrometry) in
two independent experiments (Supplementary Fig. 2a; Supple-
mentary Data 2 and 3)27. We found a high correlation of iden-
tiﬁed proteins between the technical replicates (Supplementary
Fig. 2b) and identiﬁed a total of 144 proteins commonly
bound to VTRNA1.1 in two independent experiments (Fig. 2a;
Supplementary Fig. 2c). Gene Ontology (GO) analyses conﬁrmed
that we signiﬁcantly enriched for proteins binding to single and
double stranded RNAs (Fig. 2b; Supplementary Data 4).
As expected, the majority of RNA-binding proteins were not
differentially bound to methylated or un-methylated VTRNA1.1,
this included proteins related to m5C deposition (NSUN2) and
‘reading’ (ALYREF) (Fig. 2a)4. In contrast, pseudouridine
synthase 7 (PUS7) bound methylated VTRNA1.1 with higher
afﬁnity, whereas the serine/arginine rich (SR) splicing factor 2
(SRSF2) was consistently repelled by m5C in VTRNA1.1 (Fig. 2a).
To conﬁrm that we pulled down VTRNA1.1-speciﬁc RNA-
binding proteins, we performed RNA pull-down assays followed
by western blot, and found that SRSF2 bound non-methylated
(C69) with higher afﬁnity than methylated (m5C69) VTRNA1.1
(Fig. 2c). In contrast, PUS7 bound methylated VTRNA1.1 with
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Fig. 1 Methylation of VTRNA1.1 by NSUN2 determines the biogenesis of svRNA4. a–c Correlation of site-speciﬁc methylation (m5C) levels (a, b) and
methylation level at all covered cytosines in VTRNA1.1 (c) in NSUN2-/- cells infected with the empty (e.) vector (ctr), the enzymatic dead construct K190M
or the wild-type NSUN2 construct. NSUN2-speciﬁc sites are highlighted in red. d, e Heatmaps (upper panels) and methylation level (bottom panels) of
VTRNA1.1, VTRN1.3, RPPH1, and HECTD1 in infected NSUN2-/- cells (d), human embryonic ﬁbroblasts (H9) and HEK293 cells (e). Shown are ﬁve
independent bisulﬁte conversion experiments. f Schematic illustration of NSUN2-dependent methylation (CH3) of VTRNA1.1 and the small regulatory non-
coding fragments svRNA4. g Abundance of svRNA4 in the presence (+/−) and absence (−/−) of NSUN2. Methylation dead NSUN2-mutant constructs
(C271A; C321A) fail to rescue svRNA4 levels in NSUN2−/− cells. Error bars indicate s.d. (n= 3 qRT-PCR reactions). ***p < 0.001 unpaired student’s t-test.
h Log2 fold-change of NSUN2 in the indicated cells compared to NSUN2+/+control cells measured by ribosome proﬁling. Source data are provided as a
Source Data ﬁle
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higher afﬁnity (Supplementary Fig. 2d; C69, m5C69). The
heterogeneous nuclear RNP (hnRNP) A1 protein served as a
loading control (Fig. 2c)27.
m5C directly inﬂuences the afﬁnity of SRSF2 to VTRNA1.1.
SRSF2 is best-known for its role in splicing where it mediates
exon inclusion and exclusion equally well28. SRSF2 was a pro-
mising candidate to regulate VTRNA1.1 processing because SR
protein binding is not limited to pre-mRNA, they can also
associate with non-coding RNAs, such as 7SK and MALAT129–32.
SRSF2 binds to pre-mRNA via its RNA recognition motif
domain33–35, and VTRNA1.1 contained two putative SRSF2 RNA
binding motifs (RRM1 and RRM2) (Fig. 2d; Supplementary
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Fig. 2e)28,36. RRM1 overlapped with the methylated cytosine 69
(Fig. 2d). To validate the functional importance of the SRSF2
binding motifs, we point mutated C69 (C69A) and C88 (C88U)
in VTRNA1.1 and performed RNA pull-down experiments fol-
lowed by western blot for SRSF2. Both mutations decreased the
binding afﬁnity to SRSF2 (Fig. 2d; Supplementary Fig. 2f).
Interestingly, binding of PUS7 to the mutated VTRNA1.1-con-
structs was also decreased (Supplementary Fig. 2d).
To further conﬁrm a direct RNA–protein interaction between
VTRNA1.1 and SRSF2, we performed electrophoretic mobility
shift assays (EMSA) using methylated and un-methylated
VTRNA1.1 (Fig. 2e). Puriﬁed, recombinant GST-SRSF2 RNA
recognition motif (GST-SRSF2 RRM) showed high
binding afﬁnity to un-methylated VTRNA1.1 (C69) that
correlated with increased concentration of the recombinant
protein. Importantly, the binding afﬁnity of GST-SRSF2 RRM
was signiﬁcantly lower when VTRNA1.1 was methylated at C69
(m5C69) (Fig. 2e, f).
Finally, we asked whether SRSF2-binding afﬁnity to
VTRNA1.1 also decreased upon NSUN2-mediated methylation
in vivo. First, we conﬁrmed comparable protein expression levels
of SRSF2 in NSUN2-expressing (+/+; +/−) or –lacking (−/−)
cells by immunoprecipitation or western blotting (Fig. 3a, b;
Supplementary Fig. 3a). Next, we co-immunoprecipitated SRSF2
and measured bound VTRNA1.1 by qRT-PCR (Fig. 3c). The
amount of VTRNA1.1 bound to SRSF2 was highest in the absence
of NSUN2 (Fig. 3c), conﬁrming that SRSF2 preferentially bound
un-methylated VTRNA1.1.
In conclusion, we identiﬁed SRSF2 as a novel VTRNA1.1-
binding protein, whose afﬁnity was reduced by post-
transcriptional methylation of VTRNA1.1 by NSUN2.
VTRNA1.1 processing is altered in the absence of SRSF2. To
test how SRSF2 modulated the processing of VTRNA1.1, we
depleted SRSF2 in NSUN2-lacking cells for two reasons. First, the
afﬁnity of SRSF2 to VTRNA1.1 was highest in NSUN2−/− cells
(Fig. 3c). Second svRNA4 production was lowest in NSUN2−/−
cells (Fig. 1g). While SRSF1, a close protein family member of
SRSF2, was efﬁciently down-regulated using siRNA and shRNAs,
SRSF2 was consistently repressed by only 50% (Supplementary
Fig. 3b, c). However, both proteins were similarly down-regulated
on protein levels (Fig. 3d). The processing of VTRNA1.1 into
svRNA4 was signiﬁcantly increased when SRSF2 was knocked-
down (Fig. 3e). Together, these results showed that (i) SRSF2
protected un-methylated VTRNA1.1 from processing and (ii) loss
of SRSF2 was sufﬁcient to rescue svRNA4 production in the
absence of NSUN2-driven methylation. This data indicated that
SRSF2-binding to VTRNA1.1 was likely to occur up-stream of
VTRNA1.1 methylation. The processing into svRNA1 was
slightly reduced by down-regulation of SRSF1 and 2, yet this
change was not signiﬁcant (Fig. 3e). In summary, our data
demonstrated that SRSF2-binding to un-methylated VTRNA1.1
down-regulated the level of processing into svRNA4.
VTRNA1.1, svRNA4 and SRSF2 levels are dynamically regu-
lated. We next asked whether SRSF2-regulated VTRNA1.1 pro-
cessing was physiologically relevant. Because removal of SRSF2
can cause cell death37, we turned our studies to primary human
keratinocytes (HK), which are highly resistant to apoptosis38.
Primary HK can be cultured as undifferentiated, lineage com-
mitted progenitor cells and induced to terminally differentiate by
exposure to high calcium concentration in the culture medium39.
Using the calcium switch assay, we differentiated epidermal cells
for 2 and 6 days (Fig. 4a).
First, we conﬁrmed that RNA expression levels of the
epidermal differentiation markers keratin 10 (Krt10), transgluta-
minase I (Tgm), involucrin (Inv), and the epidermal differentia-
tion regulator Ovo Like Transcriptional Repressor 1 (Ovol1) were
all up-regulated at both time points (Fig. 4b)40,41. Notably, also
the abundance of full-length VTRNA1.1 signiﬁcantly increased
upon differentiation (Fig. 4b). In contrast, the RNA levels of Srsf2,
Nsun2 and svRNA4 were all repressed upon differentiation
(Fig. 4c). Together, these data indicated that both methylation of
RNAs by NSUN2 and VTRNA1.1 processing was highest in
undifferentiated epidermal progenitor cells.
m5C levels are dynamic and depend on the type of RNA. To
directly determine the methylation differences in undifferentiated
and differentiated epidermal cells, we performed RNA bisulﬁte
(BS) sequencing7,42. We only quantiﬁed sites with a coverage of
more than 100 reads and a minimum of 20% methylation in at
least one of the two conditions (Supplementary Data 5). The
average methylation level of the around 350 identiﬁed sites was
signiﬁcantly higher in the undifferentiated cells (Fig. 4d). We
conﬁrmed comparable coverage of these sites in the two condi-
tions (Fig. 4e). Next, we compared the methylation levels of
NSUN2-dependent and high conﬁdence sites, which we deﬁned
as all rescued sites found in the NSUN2−/− human dermal
NS
un
2+
/+
NS
un
2+
/–
NS
un
2–
/–
NS
un
2–
/–
NSUN2
Tubulin
100 kDa
50 kDa
Tubulin
SRSF2 35 kDa
50 kDa
a
b
NS
un
2+
/+
NS
un
2+
/–
NS
un
2–
/–
0
1
2
3
4
5
F
C
 to
 a
nt
ib
od
y 
ct
r 
c
*
**
SRSF2-bound VTRNA1.1
d
SRSF2
TUBB
Em
pt
y V
. 
Em
pt
y V
.
Sh
RN
A1
.1
Sh
RN
A1
.6
Sh
RN
A2
.4
Sh
RN
A2
.5
e
0
1
2
3
F
C
 v
er
su
s 
e.
V
.
Sh
RN
A 
SR
SF
1
Sh
RN
A 
SR
SF
2
Sh
RN
A 
SR
SF
1
Sh
RN
A 
SR
SF
2
Em
pt
y V
.
Em
pt
y V
.
svRNA1 svRNA4
n.s.
**
NSun2–/–
35 kDa
35 kDa
50 kDa
50 kDa
SRSF1
TUBB
Fig. 3 Methylation-guided VT-RNA1.1 processing is altered in the absence of
SRSF2. a, bWestern blot for endogenous SRSF2 (a) and NSUN2 (b) in NSUN2-
expressing (+/+, +/−) and -lacking (−/−) human ﬁbroblasts (from two
patients). Tubulin served as a loading control. c qRT-PCR measuring SRSF2-
bound VTRNA1.1 normalised to the control (ctr; Rabbit serum conjugated with
Dynabeads) after recovering the pulled down RNA in the SRSF2
immunoprecipitation. d Western blot for SRSF1 and SRSF2 in NSUN2−/−
human ﬁbroblasts infected with shRNAs (1.1, 1.6, 2.4, 2.5). Tubulin served as a
loading control. e Fold-change (FC) of svRNA1 and 4 abundances after knock-
down of SRSF1 and 2, relative to NSUN2−/− cells infected with the empty
vector (e.V.). Shown are the pooled values using the two shRNA constructs
shown in (d). Error bars indicate s.d. (n= 3-6 qRT-PCRs). **p <0.01 students
t-test. Source data are provided as a Source Data ﬁle
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10020-7 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:2550 | https://doi.org/10.1038/s41467-019-10020-7 | www.nature.com/naturecommunications 5
ﬁbroblasts (n= 76) (Supplementary Data 6). The vast majority of
these sites were located in tRNAs and a small number occurred in
other non-coding RNAs (Fig. 4f). In contrast to all sites detected
in the epidermal cells, most of these NSUN2-methylated RNAs,
including VTRNA1.1, showed higher methylation levels in the
differentiated condition (Fig. 4f–h). The higher level of
methylation was consistent in all replicates (Fig. 4g, h; right hand
panels).
One explanation why speciﬁcally these NSUN2-dependent
methylation sites were more abundant in differentiated cells was
that they all occurred in abundant and stable non-coding RNAs.
Due to their long half-life, the methylated forms might
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accumulate during differentiation, provided the processing
machinery ‘reading’ the presence or absence of the methyl mark
was less active in differentiating cells. This hypothesis was
supported by our ﬁnding that full-length VTRNA1.1 was more
abundant in differentiated epidermal cells, while svRNA4
decreased (Fig. 4b, c). In addition, VTRNA1.1 was consistently
better covered in differentiated cells by BS sequencing (Supple-
mentary Fig. 4a). Similarly, the coverage of tRNA LeuCAA was
reduced in undifferentiated cells and it also showed higher
methylation levels at NSUN2-speciﬁc sites in the differentiated
cell state (Fig. 4h; Supplementary Fig. 4b). Moreover, higher
coverage also negatively correlated with expression of NSUN2 in
the human dermal ﬁbroblasts (Supplementary Fig. 4a, b). Thus,
our data indicated that the overall methylation levels of stable
non-coding RNAs depended on the presence of both the
methylating enzyme and the RNA processing machinery.
svRNA4 maintains undifferentiated transcriptional pro-
gramme. To provide direct evidence that both the presence of
NSUN2 and VTRNA1.1 processing was required in the undif-
ferentiated progenitor cells, we transfected a svRNA4 mimic into
primary HK and differentiated them using the calcium switch
assay (Fig. 4i). svRNA4-transduced keratinocytes failed to
undergo the morphological changes that are normally associated
with a stratiﬁed squamous epithelium (Fig. 4i)43. To conﬁrm a
reduced capacity to differentiate in the presence of svRNA4, we
measured RNA and protein expression levels of terminal differ-
entiation markers. Western blot for the differentiation marker
KRT10 and OVOL1 revealed repression of both markers in the
presence of svRNA4 (Fig. 4j). QRT-PCR further conﬁrmed down-
regulation of RNA expression levels of the terminal differentia-
tion markers Krt10, Inv, and Tgm as well as Nsun2 and Myc, both
known to promote lineage commitment in skin (Fig. 4k)9,44–46.
Importantly, inhibition of endogenous svRNA4 using an anti-
svRNA construct was sufﬁcient to reverse the abundance of the
terminal differentiation markers of Tgm, Inv, and Ovol1 even in
low calcium growth conditions (Fig. 4l). The low abundance of
full-length VTRNA1.1 in both experiments conﬁrmed that both
constructs efﬁciently repressed their target RNA sequences
(Fig. 4k, l). Together, our data indicated that the presence of
svRNA4 was sufﬁcient to maintain the transcriptional pro-
gramme of a committed, yet undifferentiated progenitor state.
SRSF2 maintains cell cycling of progenitor cells. Since the
presence of svRNA4 modulated human epidermal differentiation
and SRSF2 inﬂuenced svRNA4 processing, we next determined
the functional role of SRSF2 during epidermal cell differentiation.
We transfected the epidermal cells with SRSF2 siRNAs, and then
induced them to differentiate by increasing the calcium con-
centration in the growth medium (Fig. 5a). As a control, we also
transfected a SRSF1 siRNA, and conﬁrmed that only SRSF2
expression levels were reduced after knock-down with the SRSF2-
speciﬁc siRNA on both RNA and protein levels (Fig. 5b; Sup-
plementary Fig. 5a). As expected, the human keratinocytes
underwent efﬁcient differentiation and only Ovol1 RNA levels
were signiﬁcantly increased in the absence of SRSF2 (Fig. 5c).
These data indicated that the differentiation programme was
largely unaffected by depletion of SRSF2.
Terminal differentiation of epidermal cells is deﬁned by both
the up-regulation of differentiation markers and exit from the cell
cycle47. We noted that the SRSF2-depleted HK showed
differences in the distribution of cell cycle phases when compared
to the differentiated control keratinocytes (Supplementary
Fig. 5b). Therefore, we next asked whether SRSF2 inﬂuenced cell
division and removed Srsf2 in undifferentiated HK for 48 and 72
h (Supplementary Fig. 5c). Only after 72 h of knock-down, we
measured a signiﬁcant up-regulation of the terminal differentia-
tion markers Krt10 and Tgm (Fig. 5d). In contrast, we found a
consistent down-regulation of major cell cycle regulators as early
as 48 h after transfection (Fig. 5e)48,49. Cell cycle analyses revealed
that repression of SRSF2 led to a signiﬁcant increase of the Sub-
G1 phase of the cell cycle, indicating enhanced cell death of the
transfected HK (Fig. 5f). Indeed, keratinocytes failed to survive
longer than 72 h after SRSF2 depletion (Fig. 5g). Thus, SRSF2 is
required for cell division and survival of primary human
keratinocytes.
NSUN2 and SRSF2 act in concert to process VTRNA1.1.
Finally, we asked whether the production of svRNA4 required
both NSUN2 and SRSF2 in the primary human keratinocytes.
Since depletion of SRSF2 caused substantial cell death after 72 h,
we removed NSUN2 and SRSF2 for only 24 h to obtain the
maximum number of viable cells (Fig. 5g). As described for the
human dermal ﬁbroblasts (hDF) (Fig. 1g), knock-down of
NSUN2 in keratinocytes reduced the processing of VTRNA1.1
into svRNA4. However, the svRNA4 level was restored to normal,
when we simultaneously repressed NSUN2 and SRSF2 for 24 h
(Fig. 5h). The data was in line with our observation in human
dermal ﬁbroblasts, where removal of SRSF2 rescued the levels of
svRNA4 in NSUN2−/− patient-derived cells (Fig. 3e). and con-
ﬁrmed that binding of SRSF2 to un-methylated VTRNA1.1
reduced its processing into svRNA4. We concluded that
VTRNA1.1 processing required both NSUN2 and SRSF2 to
maintain an undifferentiated cell state.
In summary, our study revealed that SRSF2 bound un-
methylated VTRNA1.1 with higher afﬁnity and thereby protected
it from both methylation and cleavage. High levels of svRNA4 in
the presence of both proteins allowed cell cycle progression but
reduced expression of the differentiation-promoting transcription
factor OVOL1 and other terminal differentiation markers (Fig. 5i).
Fig. 4 VTRNA1.1 methylation and processing are altered during cell differentiation. a Treatment regime of keratinocytes using calcium switch assay.
b, c qRT-PCR to measure RNA levels of up-regulated (b) and down-regulated (c) markers at 2 and 6 days after calcium treatment compared to the 0 day
control. Error bars indicate s.d. (n= 3 qRT-PCRs) ****p < 0.0001, ***p < 0.001, **p < 0.01 multiple t-tests. d Methylation levels (n= 5 BS conversion
reactions) at cytosines in RNA isolated from undifferentiated (undiff) and differentiated (diff) primary HK shown as box plots showing all points with
minimum to maximum values. ****p < 0.0001 Mann Whitney test. e Log2 coverage (n= 5 BS conversion reactions) of sites in RNA isolated from
undifferentiated (undiff) and differentiated (diff) primary HK. f Correlation between methylation levels at cytosines in undifferentiated and differentiated
primary HK. Elevated methylation levels at tRNAs (examples in blue) and VTRNA1.1 (red). g, h Methylation levels in VTRNA1.1 (g) and tRNA Leu CAA (h)
in the indicated cells (left hand panels) and heat maps (right hand panels) showing methylation levels in the individual replicates. i Light microscope image
comparing the morphology of primary HK transfected with a control siRNA (Ctr) or svRNA4 after 4 days of differentiation in high CaCl2. Scale bar: 50 μm.
j Western blot detecting KRT10 and OVOL1 in HK transfected with Ctr siRNA or svRNA4 four days after calcium-induction. Tubulin served as loading
control. k, l Treatment regimes and transfection (upper panels) of svRNA4 (k) or anti-svRNA4 (l) and qRT-PCR (lower panels) to measure RNA levels of
the indicated markers 4 days after calcium treatment. Error bars indicate s.d. (n= 3 qRT-PCRs). ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05 student’s
t-test. Source data are provided as a Source Data ﬁle
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10020-7 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:2550 | https://doi.org/10.1038/s41467-019-10020-7 | www.nature.com/naturecommunications 7
NSUN2
svRNA4
OVOL1
a
–1
0
1
2
K
rt
10
T
gm
Itg
a6
siRNA Ctr Srsf2 48 h Srsf2 72 h
** *
C
dk
1
C
dc
45
C
dc
25
M
cm
10
–4
–3
–2
–1
0
1
siRNA Ctr Srsf2 48 h Srsf2 72 h
**** ************
**** **** ***
C
tr
0
2
4
6
G0/G1 G2/M S sub G1
N
o 
of
 c
el
ls
 F
C
/c
tr
 
S
rs
f2
g
sv
R
N
A
4/
m
ir1
6
0.0
0.2
0.4
0.6
0.8
S
rs
f2
S
rs
f2
+
N
su
n2C
trsiRNA:
N
su
n2
Lo
g 2
 F
C
/c
on
tr
ol
Lo
g 2
 F
C
/c
tr
O
vo
l1
T
gm
1
K
rt
10 Iv
l
b
SRSF2
TUBB
siRNA:
S
rs
f2
C
tr
35 kDa
50 kDa
Days
0
2
4
6
CaCl2
S
rs
f2
si
R
N
A
S
am
pl
e
co
lle
ct
io
n
0.0
1.0
2.0
V
tr
na
1.
1
**
c
d e
f
siRNA C
tr
S
rs
f2 C
tr
S
rs
f2 C
tr
S
rs
f2
72 h KD
**
h
Terminal differentiatedProgenitor
SRSF2
i
siRNA:
C
tr
S
rs
f2
**
**
72
 h
 K
D
C
tr
S
rs
f24
8 
h 
K
D
Fig. 5 SRSF2 is required for cell cycle and survival of undifferentiated cells. a Treatment regime and transfection of differentiating primary human
keratinocytes. b Western blot detecting SRSF2 after treatment with Srsf2 siRNA. Tubulin (TUBB) serves as loading control. c Quantiﬁcation of RNA
expression levels of Ovol1, Vtrna1.1, Tgm, Krt10, and Ivl after 6 days of calcium-induced differentiation vs. untreated control (0 days). FC: Fold-change. Error
bars indicate s.d. (n= 3 qRT-PCRs). **p < 0.01 two-way ANOVA. d, e Log2 RNA fold-change (FC) of differentiation markers (d) and cell cycle regulators
(e) after 48 and 72 h of Srsf2 knock-down. Data shown as box plot with mean showing all data from minimum to maximum (n= 4). ****p < 0.0001, ***p <
0.001, **p < 0.01, *p < 0.05 Two-way ANOVA. f Cell cycle distribution of primary HK transfected with the Srsf2 siRNA for 72 h. Error bars Data shown as
box plot showing all data from minimum to maximum (n= 10 Flow sorts). ****p < 0.0001 Two-way ANOVA. g Light microscope images of HK transfected
with a control (ctr) siRNA (upper panels) and a Srsf2 siRNA (lower panels) after 48 and 72 h in low calcium medium. Scale bar: 50 μm. h Small RNA qRT-
PCR measuring the abundance of svRNA4 in primary HK transfected with the indicated siRNA constructs. Data shown as box plot with mean showing all
data from minimum to maximum. Error bars represent s.d. (n= 4 qRT-PCRs). **p < 0.01 unpaired student’s t-test. i Illustration how levels of NSUN2,
svRNA4, SRSF2, and OVOL1 change upon terminal differentiation in keratinocytes. Source data are provided as a Source Data ﬁle
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10020-7
8 NATURE COMMUNICATIONS |         (2019) 10:2550 | https://doi.org/10.1038/s41467-019-10020-7 | www.nature.com/naturecommunications
Thus, the presence and expression levels of both NSUN2 and
SRSF2 coordinated how much methylated VTRNA1.1 was
processed into svRNA4 (Fig. 6a–c).
Discussion
The proper formation of m5C in tRNA is required for normal
development7. Aberrant deposition of m5C into tRNAs causes
neuro-developmental deﬁcits by impairing the translation
machinery2,8. While the functional role of m5C in tRNA is now
increasingly understood, the importance of m5C in other non-
coding RNAs remains unclear. NSUN2 is one of the best char-
acterised cytosine-5 RNA methylases and methylates the vast
majority of tRNAs. Here, we conﬁrm that NSUN2 also methylates
the vault RNA VTRNA1.1 in a wide range of human cells.
NSUN2 is the sole enzyme to methylate cytosine 69 in
VTRNA1.1 and thereby regulates its processing into multiple
regulatory small RNAs (svRNAs).
RNA modiﬁcations control the fate and function of RNA
molecules by recruiting or repelling speciﬁc RNA binding pro-
teins50. To determine the functional relevance of m5C69 on
VTRNA1.1 metabolism, we identiﬁed all RNA-binding proteins
that bind methylated or un-methylated VTRNA1.1 with different
afﬁnity. Our quantitative mass spectrometry-based approach
identiﬁed SRSF2 as a novel VTRNA1.1 binding protein that was
repelled by the presence of m5C69. During gene transcription,
SRSF2 contributes to constitutive and alternative splicing by
binding to exonic splicing enhancer sequences (ESE), pre-
dominantly within intron-containing pre-mRNA33,34. In addi-
tion, SRSF2 binds mRNAs via non-ESE sites, for instance the
HIV-1 tat mRNA51. We identiﬁed two SRSF2 binding sites in
VTRNA1.1, one of which overlapped with the methylated C69.
SRSF2 has been described to bind other non-coding RNAs such
as 7SK and MALAT130–32. The binding of MALAT1 or 7SK is
thought to inﬂuence the recruitment of SRSF2 to distinct active
transcriptional regions30,32. Nuclear un-methylated VTRNA1.1
might have a similar function.
In addition to their roles in splicing, SR proteins are thought to
have a broader role in RNA metabolism. SRSF1, for instance,
facilitates the processing of certain microRNAs independent of its
function in splicing52. Furthermore, CLIP assays revealed little
direct correlation between SRSF2 protein binding and induced
splicing changes31. Here, we propose that SRSF2 contributes to
VTRNA1.1 processing into svRNA4 binding to un-methylated
VTRNA1.1 and thereby protecting it from methylation by
NSUN2 (Fig. 6a). For instance, epidermal progenitors express
high levels of both NSUN2 and SRSF2 and consequently,
methylate a substantial fraction of VTRNA1.1. Methylated
VTRNA1.1 binds SRSF2 with lower afﬁnity and the levels of
svRNA4 increase. Deletion of NSUN2 leads to loss of m5C at C69
and enhances the binding of VTRNA1.1 to SRSF2 (Fig. 6b).
Binding to SRSF2 reduced the level of VTRNA1.1 entering the
RNA processing machinery leading to reduced production of
svRNA4. Finally, we tested a scenario where both proteins are
repressed (Fig. 6c). This enhanced the fraction of free VTRNA1.1
that entered the RNA processing machinery leading to increased
levels of svRNA4. Together, VTRNA1.1 methylation at C69
facilitates the production of svRNA4 by reducing SRSF2 afﬁnity
to VTRNA1.1.
Deciphering the precise function of SRSF2 in modulating the
processing of VTRNA1.1 was hampered by the fact that SRSF2 is
an essential protein upstream of both RNA methylation and
processing. Homozygous germ line deletion of SRSF2 is
embryonic lethal53, and conditional knock-out mice display
tissue-speciﬁc phenotypes53–56. Similar to repression of SRSF2 in
epidermal progenitors, loss of SRSF2 in mouse embryonic
ﬁbroblasts induced G2/M cell cycle arrest and genomic instabil-
ity54. In addition, SRSF2 is required to maintain human
embryonic stem cell pluripotency57. Mutations in the human
SRSF2 gene altering its RNA-binding afﬁnity impairs hemato-
poietic differentiation in vivo and is frequently (40% incidence)
found in patients with myelodysplastic syndromes and certain
leukaemias28,58,59.
The function of SRSF2 in splicing might be modulated by
VTRNA1.1, yet VTRNA1.1-methylation and processing are
probably not linked to splicing. Repression of SRSF2 in primary
human keratinocytes caused cell cycle arrest and cell death, and
this effect was independent of VTRNA1.1-methylation and
processing. However, simultaneous deletion of SRSF2 and
NSUN2 increased svRNA4 levels conﬁrming that SRSF2 is
involved in regulating VTRNA1.1 processing in primary human
keratinocytes. Thus, NSUN2 and SRSF2 together determined
how much VTRNA1.1 was processed into svRNAs. Finally, we
conﬁrmed a functional relevance of svRNA4 in regulating epi-
dermal differentiation. One explanation for how svRNA4
modulated epidermal differentiation is through post-
transcriptional silencing of mRNA targets. Our previous bioin-
formatic analysis identiﬁed OVOL1 as a high conﬁdence target of
RNA
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Fig. 6 Summary of VTRNA1.1 processing into svRNA4. a Expression of both NSUN2 and SRSF2 (e.g. in progenitor cells) result in high levels of VTRNA1.1
methylation (CH3) and high levels of svRNA4 and repressed differentiation. b No NSUN2 in the presence of SRSF2 suppresses formation of svRNA4 and
allows differentiation. c Lack of expression of both NSUN2 and SRSF2 release VTRNA1.1 from SRSF2 binding and increases the levels of svRNA4
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svRNA43. While we indeed found an inverse relationship
between the abundances of OVOL1 and svRNA4, more work is
needed to conﬁrm that svRNA4 indeed acts similarly to miR-
NAs. However, we identiﬁed a functional relevance for svRNA4
in regulating the terminal differentiation program. While
enhanced levels of svRNA4 repressed the terminal differentiation
program, sequestering svRNA4 was sufﬁcient to trigger
differentiation.
Methods
Cell culture, transfections and infections. HEK293 and HeLa cells (ATCC) were
grown in Dulbecco’s Minimal Essential Medium (DMEM) (Thermo Fisher Sci-
entiﬁc) supplemented with 10% foetal bovine serum (FBS) (Sigma), penicillin, and
streptomycin. Human dermal ﬁbroblasts11 were grown in Minimal Essential
Medium (MEM) (Thermo Fisher Scientiﬁc) supplemented with 20% FBS (Sigma),
1% penicillin, and streptomycin. The human embryonic stem cell line Hues9 (H9)
was obtained from the WiCell. H9 cells were maintained in Essential 8 media
(Thermo Fisher Scientiﬁc) on human embryonic stem cell-qualiﬁed matrigel
(Corning) coated plates at 37 °C, 5% CO2. Primary human keratinocytes isolated
from neonatal foreskins (Cellworks distributed, ZHC-1116) were cultured on
collagen (BD Biosciences) coated plates in KGM-gold (Lonza) medium. For cell
propagation calcium concentrations were adjusted to 0.06 mM using 1.2 M CaCl2
stock solution. Medium was changed every other day and cells were passaged when
reaching 60–70% conﬂuency. For epidermal differentiation, KGM-gold calcium
concentrations were adjusted to 1.2 mM using 1.2 M CaCl2 stock solution. Primary
human epidermal cells were only used until passages 6–7 after thawing. All cells
were cultured in humidiﬁed atmospheres with 5% CO2.
For the transfection of small interfering RNA (siRNA), human dermal
ﬁbroblasts and primary human keratinocytes (HK) cells were cultured until
reaching 50–60% conﬂuency. Cells were then transfected with a control siRNAs or
svRNA4 antagomirs (2′-O-methyl-anti-svRNA4: 5′ AAA AGG ACU GGA GAG
CGC CCG CGG GUC UCG); control microRNA miRIDIAN mimic or svRNA4
microRNA miRIDIAN mimic (5′ CGA GAC CCG CGG GCG CUC UCC AGU
CCU UUU) (Dharmacon-GE); SRSF1 siRNAs (QIAGEN) or SFSF2 siRNAs
(QIAGEN, and Dharmacon-GE) using RNAimax transfection kit (Thermo Fisher
Scientiﬁc). 24, 48, or 72 h post-transfection, cells were washed in PBS and RNA or
protein was isolated.
For the infection of the short hairpin (sh) RNA, the most effect siRNAs were
clones into PLKO.1 puro plasmids (Addgene). To produce the lentivirus,
HEK293T cells were grown in DMEM supplemented with 10% FBS on 60 cm cell
dishes until 40–50% conﬂuent and then transfected with 15 μg lentiviral PLKO.1
puro vectors containing shRNA for SRSF1 (shRNA1.1, shRNA1.6) or SRSF2
(shRNA2.4, shRNA2.5) or the empty PLKO.1 puro vector and 7.5 μg of both
packaging vectors (Pol and Gag) using the calcium-phosphate transfection kit
(Thermo Fisher Scientiﬁc). The next day the medium was carefully changed to
avoid detaching HeK293T cells and kept in culture for another 24 h. Subsequently,
supernatant containing viral particles were collected and ﬁltered (0.22 μm) before
being used to infect human dermal ﬁbroblast. The next day, the medium was
changed, and cells were kept in culture for 24 h before selecting with 1 μg/ml
puromycin for 4 days with medium changed after day 2. After selection, the
ﬁbroblasts were propagated without purpmycin for further experiments.
To rescue expression of NSUN2 protein or its enzymatic dead version, full-
length human NSUN2 (pB-NSUN2), inactive mutants C271A (pB-NSUN2-
C271A), K190M (pB-NSUN2-K190M) or C321A (pB-NSUN2-C321A), and the
empty vector (pB-empty) were infected retrovirally26.
RNA bisulﬁte sequencing. All RNA bisulﬁte conversion experiments were per-
formed in ﬁve independent replicates. Total RNA of about 4 μg was extracted using
Trizol (Thermo Fisher Scientiﬁc) and then DNase (Ambion) and Ribo‐Zero
(Illumina) treated according to the manufacturers’ instruction. The remaining
RNA fraction was bisulﬁte‐converted. Brieﬂy, ribosomal depleted RNA was mixed
with 70 μl of 40% sodium bisulﬁte pH 5.0 and DNA protection buffer (EpiTect
Bisulﬁte Kit, Qiagen). The reaction mixture was incubated for three cycles of 5 min
at 70 °C followed by 1 h at 60 °C and then desalted with Micro Bio‐spin 6 chro-
matography columns (Bio‐Rad). RNA was desulphonated by adding an equal
volume of 1M Tris (pH 9.0) to the reaction mixture and incubated for 1 h at 37 °C,
followed by ethanol precipitation. Bisulﬁte converted RNA was then treated with
T4 PNK (New England Biolabs) to repair both 5′ and 3′ ends for library pre-
paration. Repaired RNA quality and concentration was measured on a Bioanalyzer
2100 RNA nano‐chip (Agilent). About 100 ng of RNA was used to generate the
libraries using the TruSeq Small RNA preparation kit (Illumina). RNA adapters
were then ligated, reverse‐transcribed and ampliﬁed by 18 cycles of PCR before
sequencing on a HiSeq4000 (Illumina).
Small qRT-PCR and qRT-PCR. To measure the abundance of svRNA1 and
svRNA4 we performed small quantitative PCR (qRT-PCR). Total RNA from
human epidermal cells, NSUN2+/−, NSUN2−/− dermal ﬁbroblasts was isolated
using TRIzol according to the manufacturer’s instruction (Thermo Fisher
Scientiﬁc). RNAs of smaller than 200 base pairs were enriched using mirVana kit
(Ambion) according to the manufacturer’s instructions. Enriched RNAs were
then separated using 15% acrylamide-urea gels (Thermo Fisher Scientiﬁc) and
gel slices spanning 10–40 bps were excised and crushed in RNase free water and
incubated overnight at 4 °C. Eluted RNA was then puriﬁed using spin-X cen-
trifuge tube ﬁlters (0.22 μM) (Costar) and ethanol precipitated over night at
−20 °C. Small RNA reverse transcription and qRT-PCR was performed as fol-
lows60. PolyA tails were added to small RNAs using poly(A) polymerase
(Ambion). The poly(T) primer 5′-GCG AGC ACA GAA TTA ATA CGA CTC
ACT ATA GG(T)12VN-3′ was then used for cDNA synthesis. QuantifastSYBR®
green master mix (QIAGEN) was used for qRT-PCR reactions. cDNA was
incubated at 90 °C for 10 min followed by 40 cycles of 30 s denaturation at 90 °C,
and 1 min of extension at 60 °C. The forward primers were: miR-16 (5′-TAG
CAG CAC GTA AAT ATT GGC G-′3), svRNA1 (5′-TGT CTG GGT TGT TCG
AGA CCC GCG GGC-3′), and svRNA4 (5′-CGA GAC CCG CGG GCG CTC
TCC AGT CCT TTT-′3). The reverse primer for all reactions was: 5′-GCG AGC
ACA GAA TTA ATA CGA C-3′.
For conventional quantitative PCR (qRT-PCR) total RNA was isolated from
human ﬁbroblasts, and primary human keratinocytes cells using TRIzol (Thermo
Fisher Scientiﬁc). cDNA synthesis was performed using the SuperscriptIII reverse
transcriptase kit (Thermo Fisher Scientiﬁc) according to manufacturer’s
instructions. qRT-PCR was performed using TaqMan assay sets purchased from
Thermo Fisher Scientiﬁc and used as per manufacturer’s recommendations or pre-
designed primers (Sigma-Aldrich) and Sybr master mix 2 × (Life Technologies)
were used. The following probes were used to amplify selected genes: Gapdh
(4326317E), Nsun2 (Hs00214829_m1), Srsf2 (Hs00958207_cn), Srsf1
(Hs00199471_m1), Ovol1 (Hs00190060_m1), vt-RNA1.1 (Hs03676993_s1), Inv
(Hs00846307_s1), Tgm1 (Hs00165929_m1 and Hs01070316_m1), Krt10
(Hs01051614_g1 and Hs00166289_m1), Myc (Hs00153408_m1), Itgα6
(Hs01041013_m1), Cdc45 (Hs00907337_m1), Mcm10 (Hs00960349_m1), Cdc25
(Hs00156411_m1), and Cdk1 (Hs00938777_m1). The following pre-designed
primers were used: Gapdh (forward: ATC TTC CAG GAG CGA GAT CC, reverse:
ACC ACT GAC ACG TTG GCA GT), Srsf2 (forward: CCT AAT TTG TGG CCT
CCT GA, reverse: TCA ATC TCT TGA CAG CT TAG GC).
SILAC. HeLa cells were grown in SILAC DMEM (Thermo Fisher Scientiﬁc) sup-
plemented with either “light” L-lysine-2HCl and L-arginine-HCl or “heavy” 13C6-
L-lysine-2HCl and 13C615N4-L-arginine-HCl. For full incorporation of “light” or
“heavy” L-Lys/L-Arg, for at least six passages. Subsequently, 3 × 106 cells were re-
suspended in 1 ml of buffer-D (100 mM Tris-HCl at pH 8.0; 100 mM KCl; 0.2 mM
EDTA; 0.5 mM DTT; 0.2 mM PMSF; 20% (w/v) glycerol), scraped and sonicated
(Diagenode). The suspension was centrifuged for 5 min at 10,000 × g, and the
supernatant was used for VTRNA pull-down assays followed by mass spectrometry
detection61
RNA pull-down and SILAC mass-spectrometry (RP-SMS). We performed
agarose mediated VT-RNA1.1 pull-downs62,27. Brieﬂy, 10 μg of methylated, or un-
methylated VT-RNA1.1 (Dharmacon-GE) was treated with sodium m-periodate
(Sigma) for 1 h at room temperature while rotating. VT-RNAs were then pre-
cipitated by 3M of sodium acetate (Ambion) and ethanol. Recovered VT-RNAs
were then covalently coupled with adipic acid dihydrazide agarose beads (Sigma)
overnight at 4 °C. VT-RNA-bead complex was incubated with 40% v/v of total
SILAC “heavy” HeLa lysates supplemented with 1.5 mM MgCl2, 25 mM creatine-
phosphate (Millipore), 200 units per ml RNAseOUT (ThermoFisher Scientiﬁc) and
5 mM ATP (Sigma) for 30 min at 37 °C. The beads only control was incubated with
SILAC “light” HeLa lysates. The reactions were washed four times with Buffer-G
(20 mM Tris-HCl at PH7.5; 137 mM NaCl; 1 mM EDTA; 1% Triton x100; 10%
glycerol; 1.5 mM MgCl2) or Buffer-A (20 mM Tris-HCl at pH: 7.5; 50 mM NaCl;
1 mM EDTA; 1% NP-40; 10% glycerol; 1.5 mM MgCl2), for less stringent RNA-
protein interactions. After the ﬁnal wash, RNA-bead complex was mixed with
beads only control and incubated in 60 μl H2O containing 4x LDS protein sample
buffer (Novex), 10X reducing reagent buffer (Novex), then incubated at 70 °C for
10 min. The end solution was centrifuged at maximum speed for 1 min and the
supernatant was collected and analysed either by quantitative mass-spectrometer or
SDS-PAGE western blot for proteins detection27.
RNA immunoprecipitation (RIP). Pelleted human dermal ﬁbroblasts were lysed in
RIP buffer (1% NP-40; 25 mM Tris-HCl at pH 8.0; 150 mM NaCl; 2 mM MgCl2; 1
mM DTT) and incubated on ice for 30 min. SRSF2 antibody (5μ ab11826; Abcam),
or control pre-bled serum were pre-incubated with Protein G magnetic dynabeads
(Thermo Fisher Scientiﬁc) in lysis buffer for 30 min. Following washing of beads,
cleared lysates were added to the beads and immunoprecipitation was carried out
for 2 h at 4 °C with gentle mixing. Beads were then washed extensively in lysis
buffer and precipitated RNAs were recovered from the beads using TRIzol
(Thermo Fisher Scientiﬁc). Immunoprecipitation reactions were performed in the
presence of 200 units per ml of RNAse inhibitor.
Co-immunoprecipitations and western blot. Conﬂuent 150 cm dishes of cells
were washed twice with ice-cold PBS before being scraped using 300 μl of ice-cold
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CHAPS (FIVE photon Biochemicals) lysis buffer supplemented with protease
inhibitors (Roche) and phosphatase inhibitors (Roche). Lysates were transferred to
pre-chilled Eppendorf tubes and incubated on ice for 10 min. Tubes were strongly
taped several times during the incubation period to facilitate cell membrane lysis.
Lysates were centrifuged for 15 min at maximum speed under cool conditions. The
supernatant was stored until used for co-IP analysis. About 3 μg of primary anti-
bodies or control pre-bled serum were washed three times with PBS before incu-
bated with CHAPS prepared HeLa lysates at 4 °C for 1 h. During incubation period
50 μl of Agarose Anti-Rabbit IgG IP beads (ROCKLAND) was washed extensively
with pre-chilled lysis buffer (50 mM Tris-HCl pH: 8; 150 mM NaCl; 1% NP-40;
protease inhibitor; phosphatase inhibitor). After the incubation, Agarose Anti-
Rabbit IgG IP beads were added to the mixture and left rotating overnight at 4 °C.
The samples were then centrifuged at 1000 × g for 1 min and the supernatant was
removed. The pelleted bead-antibody complex was washed four times with lysis
buffer. The bead-antibody complex was then mixed with 4× LDS sample buffer
(Novex), and 10× reducing reagent buffer (Novex) and incubated at 70 °C for 10
min for western blotting detection.
For western blotting, cells were harvested and washed twice with PBS before
being lysed with lysis buffer (50 mM Tris-HCL at pH 7.4; 250 mM NaCl; 1% NP-
40; 0.1% SDS; 0.5% sodium deoxycholate) and were cleared by centrifugation at full
speed for 10 min at 4 °C. Supernatant was mixed with 4× LDS protein sample
buffer (Novex), 10× reducing reagent buffer (Novex) and incubated at 70 °C for 10
min. Samples were run on running buffer (Novex) containing 40× NuPAGE
Antioxidant (Novex) then electrophoresed on a 4–12% Bis-Tris precast
polyacrylamide gels (Novex). Proteins were transferred onto nitrocellulose
membranes (GE Healthcare) using transfer buffer (191 mM Glycine; 25 mM Tris-
hydrochloride; 10% Methanol; 0.1% SDS). Nitrocellulose membranes were blocked
in 10% western Blocking Reagent (Roche). Blots were then incubated with primary
antibodies in blocking solution overnight at 4 °C then followed by incubation with
the appropriate HRP-conjugated secondary antibodies. The chemiluminescent
signal was detected using an ECL chemiluminescent kit (GE Healthcare) according
to instructions. The following antibodies were used: NSUN2 (1:1000; Met-A)63,
hnRNP-A1 (1:2000; D21H11; Cell Signalling Technology), SRSF2 (1:1000;
ab11826; Abcam), SRSF1 (1:2000; 32–4500; Thermo Fisher Scientiﬁc), OVOL1
(1:1000; ab65023; Abcam), KRT10 (1:2000; PRB-159P; Covance), Tubulin (1:5000;
clone DM1A; Sigma), PUS7 (1:2000; ab118039, Abcam).
EMSA. EMSA was performed with end-labelled vtRNA1.1 and indicated amounts
of recombinant GST-SRSF2 RRM. Probes (50 × 103 counts per minute, ~0.1 pmol)
were incubated in 16 μl reactions with recombinant protein in elution buffer
(25 mM Tris-HCl, 5 mM reduced glutathione, pH 8.0) supplemented with 3 mM
MgCl2, 0.5 mM ATP, 37.5 mM creatine phosphate and 10 ng tRNA for one hour
on ice. Reactions were mixed with native loading buffer and analysed on a 6% (w/v)
non-denaturing polyacrylamide gel run in 0.5×TBE at 8W for 1 h 10 min. The
signal was registered using radiographic X-ray ﬁlm.
Cell cycle analyses. Flow cytometry was used to probe cell cycle stage. Flow
cytometry analysis was performed with the LSRFortessa Flow Cytometer (BD
Biosciences). Cells were washed in PBS and collected with Trypsin-EDTA (1:1 in
PBS). Cells were then ﬁxed by resuspending in ice-cold 70% ethanol. Samples were
kept at 4 °C until processing. Before processing cells were centrifuged at 12,000 × g
for 5 min and resuspended in 3 mL PBS with DAPI (1:3000). Fluorescence of each
samples was measured on the ﬂow cytometer at 450/50 405 nm. Data was analysed
using FCS express6 (DeNovo Software). All samples were gated using forward vs.
side scatter to eliminate debris.
Bioinformatic analyses. To assess the transcriptome-wide methylation levels and
to create the methylation level heatmaps, Trim Galore! (v0.4.0) with parameters
"--stringency 3 -e 0.2 -a TGGAATTCTCGGGTGCCAAGGA” was used to remove
sequencing adapters and reads shorter than 20 nucleotides. Alignment to the hg38
reference genome was done with Bismark (v0.14.4) with parameters “-n 2 -l 50
--un --ambiguous --bowtie1 --chunkmbs 2048”, to allow for up to two mismatches
and to save unaligned and ambiguously mapping reads separately. Seqtk with
parameters “-e 3” was used to remove the last three bases (a potential ‘CCA’ tail)
from the unaligned and ambiguous reads followed by a second alignment attempt
using Bismark. Finally, ngsutils (v0.5.9) in the “junction” mode was used to extract
splice junctions from known genes (Gencode v28) and unaligned reads from the
second attempt were aligned to the junctions using Bismark. The aligned reads
were converted back to genomic coordinates using bamutils in “convertregion”
mode. ‘N’ in the cigar string was replaced with ‘D’ for compatibility with
bismark_methylation_extractor.
To identify novel high-conﬁdence methylation sites we selected all sites with
read coverage above 10 in all replicates. Welch’s t-test was used to compare the
methylation levels of either the empty vector (e. Vector) or the enzymatic dead
version (K190M) to the Nsun2 rescue (NSUN2); ﬁve replicates per group. False
discovery rate was used to correct for multiple testing. Methylation sites with padj
< 0.05 were considered to be differently methylated.
Samtools merge was used to combine aligned reads from all three steps. Reads
with >1/3 methylated cytosines were discarded as they are likely artifacts from highly
structured regions. The bismark_methylation_extractor with the “--bedGraph
--counts --CX_context” options was used to extract methylated cytosines.
Sequencing data from patient cells are deposited on dbGaP under the accession
number phs000645.v4.p1. The sequencing data are available on GEO with the
accession numbers GSE122600 and GSE125046.
Gene set enrichment analyses were done using GOrilla [http://cbl-gorilla.cs.
technion.ac.il/]64. As running mode, we used “two ranked lists of genes” using all
identiﬁed binding proteins as background list.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Patient-related sequencing data are available on dbGaP: phs000645.v4.p1. All other
sequencing data are available on GEO: GSE122600 and GSE125046. The source data
underlying Figs. 1c, g, h; 2c-f; 3a-e; 4b, c, j-l; 5b-f, h and Supplementary Figs. 1a; 2d, f; 3a-
c; 5a and c are provided as a Source Data ﬁle. All data is available from the authors upon
reasonable request.
Code availability
The scripts used for the alignment and processing of the bisulﬁte sequencing data are
available at [https://github.com/susbo/trans-bsseq].
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